Search

everythinglearnresearchcommunity

for

Search:↓

5-alpha reductase inhibitors increase the risk of sexual dysfunction in patients treating enlarged prostate but not in those treating hair loss.

Some blood-thinning medications can increase the risk of bleeding, and certain factors like genetics and other health conditions affect their safety and effectiveness.

Parents of women with PCOS have a higher risk of Type II diabetes and insulin resistance, especially fathers.

Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.

Pregnant women with Systemic Lupus Erythematosus have a higher risk of blood clotting problems.

New research has found 14 genes linked to the risk of developing alopecia areata, improving understanding and treatment options.

Men with hormonal imbalances similar to PCOS may have increased risk of metabolic and heart diseases.

Finasteride helps improve hair growth in men with hair loss but may increase the risk of erectile dysfunction.

A woman's unique dementia was misdiagnosed, a genetic mutation increases Parkinson's risk with age, and finasteride may help with Tourette syndrome.

Dutasteride is as safe for the heart as finasteride.

Severe baldness on the top of the head is linked to a higher chance of heart disease, especially in men under 60.

Men with male pattern baldness have a higher chance of heart disease, especially if they're younger or have severe baldness; no link was found with another type of baldness called alopecia areata.

Plum-blossom needling with conventional treatments improves hair regrowth in alopecia areata.

Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.

Androgen treatment with dihydrotestosterone may help maintain height in patients with 5-α-reductase type 2 deficiency, especially before puberty.

Consider Sertoli-Leydig cell tumors in Peutz-Jeghers syndrome patients with adnexal masses.

Men may have a condition similar to PCOS, possibly indicated by early hair loss.

Topical minoxidil significantly increases hair growth in androgenetic alopecia but only some patients see cosmetically acceptable results.

Men's hair loss is not linked to their sex hormone levels, except for lower DHEAS in those with hair loss.

The document concludes that more research is needed to reduce frequent hospital visits, addiction medicine education improves with specific training, early breast cancer surgery findings are emerging, nipple smears are not very accurate, surgery for older melanoma patients doesn't extend life, a genetic condition in infants can often be treated with one drug, doctors are inconsistent with blood clot medication, a certain gene may protect against cell damage, muscle gene overexpression affects many other genes, and some mitochondrial genes are less active in mice with tumors.

Busulfan/cyclophosphamide and total bone irradiation are equally effective for AML transplants.

2% minoxidil effectively increases hair count in women with androgenetic alopecia without severe side effects.

Menopause causes dry skin, wrinkles, and hair changes, with hormone therapy helping but not recommended just for these issues.

A new method effectively detects trace sex hormones in cosmetics, ensuring safety.

Topical minoxidil may slow hair loss but often doesn't lead to satisfactory hair regrowth and requires ongoing treatment.

A new method can quickly and accurately detect illegal chemicals in hair loss products.

Common baldness is likely inherited through multiple genes, not just one.

Women with PCOS often have mood disorders and a lower quality of life, and treatment should focus on both physical and mental health.

The document concludes that managing PCOS effectively requires considering ethnic differences, obesity's impact, and ethical concerns in treatment approaches.

Melasma's causes include genetics, sun exposure, hormones, and oxidative stress, and understanding these can help create better treatments.